From: Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab
Parameter
Geometric mean
90% CI
BCD-021
Reference bevacizumab
Cmax (μg/ml)
420.93
422.53
89.12% - 111.35%
AUC (μg·h/ml)
54556.29
57999.13
80.67% - 109.69%